Navigation Links
Clarus Ventures Closes $660 Million Fund
Date:2/25/2008

Brings assets under management to $1.2 billion

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture capital firm, announced today the single close of Clarus Lifesciences II, L.P. ("Clarus II"), a $660 million fund in Limited Partner commitments. This is the second investment fund formed and managed by Clarus Ventures, since the firm was established in 2005.

Clarus II will invest $20-60 million in biotechnology, specialty pharmaceutical and medical technology companies that are developing innovative products for the treatment of human diseases. The firm's first fund has committed 90 percent of its proceeds to date.

"We have effectively completed the deployment of our first fund and built a diversified portfolio of exciting companies," said Robert Liptak, a Clarus Ventures Managing Director. "These include companies with strong growth in revenue and profitability such as Globus Medical; products near commercialization such as Sientra, Pelikan, Oxford and Zogenix; and those with breakthrough products and technologies such as Aerovance, Centaurus, CoMentis, ESBATech, Pearl, ProActa, SarCode, Taligen, and Variation. We plan to follow a similar investment strategy for Clarus II. With the diversity and depth of our team we believe we can leverage our experience to identify and help grow leading companies in the life sciences field."

The Limited Partner base for Clarus II was effectively the same as in Clarus I. A small, select group of new high-quality investors who knew the firm well also participated.

The Clarus Ventures team is led by Nicholas Galakatos, Dennis Henner, Jeffrey Leiden, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, an established group of investment professionals with deep and complementary backgrounds within the life sciences industry. The team uniquely balances broad investing expertise with leadership experience in major biotechnology and pharmaceutical companies.

About Clarus Ventures

Founded by a group of accomplished investment professionals with extensive and complementary industry backgrounds, Clarus Ventures is a life sciences venture capital firm with a team that has a long history of success in creating value. Internal operating experience combined with longstanding relationships with key opinion leaders and industry thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus Ventures augments its core expertise of investing in biopharmaceuticals and medical technology with deep and diverse expertise in research and development, commercialization, business development and operations management at the global level. The firm has $1.2 billion under management and has offices in Cambridge, Mass., and South San Francisco, CA.

For additional information on Clarus Ventures, please visit http://www.clarusventures.com.

CONTACTS:

Nicholas Galakatos, Ph.D., Clarus Ventures, Tel.: 617-949-2223

Robert Liptak, Clarus Ventures, Tel.: 617-694-2222

Tony Russo, Russo Partners, Tel.: 212-845-4251


'/>"/>
SOURCE Clarus Ventures, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
2. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
3. Khosla Ventures and BIOeCON Form KiOR Inc.
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
6. Dan Broderick Joins Prolog Ventures as Partner
7. Hank Plain Joins Morgenthaler Ventures as Partner
8. Ocera Therapeutics Closes $35.5 Million Series C Financing
9. Sinovac Closes $9.75 Million Private Placement
10. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
11. Progentix Orthobiology B.V. Closes Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... healthcare organizations to build connected digital health applications, announced a partnership with Redox, ... users to seamlessly connect to many clinical systems while keeping data secure in ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... its $200M operational capacity with its strategic internal leadership to provide clients ... quality and operational management. With office locations in North Carolina, Massachusetts, ...
(Date:2/21/2017)... --  Logicalis Healthcare Solutions , the healthcare-focused practice within ... provider ( www.us.logicalis.com ), today announced a new service ... service will help hospital CIOs make the best use ... and other clinicians immediate access to a pool of ... hospital IT staff to focus on broader issues such ...
Breaking Biology Technology:
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
Breaking Biology News(10 mins):